Infusion therapies in rheumatic practice

Infusion therapies have been used in rheumatology practice for many years. However, the recent approval of infliximab for rheumatoid arthritis and the development of a host of i.v. treatments for inflammatory rheumatic and metabolic bone disorders will likely have a significant impact on the use of infusion therapies by rheumatologists. Current i.v. therapies for rheumatic disorders include pulse corticosteroids, infliximab, cyclophosphamide, i.v. gammaglobulin, and pamidronate. This review discusses specific indications, adverse events and general requirements for administration of each of these therapies. Appropriate screening generally includes a CBC and evaluation of past allergies, renal and liver function, and cardiac status. Supplies for treatment of possible anaphylaxis should be available.